USPTO Patent Grant for Viral Infection Compounds Targeting Sigma Receptors
Summary
The USPTO has granted a patent (US12582619B2) to Thomas Jefferson University for compounds that modulate Sigma receptors to treat viral infections. The patent covers methods for preventing, treating, or ameliorating viral infections using these compounds, potentially in combination with other therapeutic agents.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12582619B2 to Thomas Jefferson University. This patent covers novel compounds, compositions, and methods for treating or ameliorating viral infections by targeting Sigma receptors, specifically Sigma-1 or Sigma-2 receptors. The disclosure highlights the potential of Sigma1 inhibitors/antagonists that induce ER stress or autophagy in disrupting virus lifecycles.
This patent grant is primarily relevant for research and development within the pharmaceutical and biotechnology sectors. While it does not impose immediate compliance obligations on regulated entities, it signifies a new intellectual property development in the therapeutic area of antiviral treatments. Companies involved in antiviral drug discovery and development should be aware of this patent for potential licensing, infringement considerations, or as a basis for further research.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds, compositions, and methods for treating or ameliorating, or preventing viral infections
Grant US12582619B2 Kind: B2 Mar 24, 2026
Assignee
Thomas Jefferson University
Inventors
Felix Jinhyun Kim, Holly Ramage
Abstract
The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and/or dissemination. The compounds contemplated in the disclosure are useful in the prevention, treatment, and/or amelioration of virus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and/or an agent that treats, ameliorates, and/or prevents one or more virus infection symptoms and/or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma1) or Sigma-2 receptor (also known as Sigma2 or TMEM97). In certain embodiments, Sigma1 inhibitors/antagonists that cause and/or trigger ER stress and/or autophagy are useful within the methods of the disclosure.
CPC Classifications
A61K 31/155 A61K 31/352 A61P 31/14 C07D 213/80 C07D 213/84 C07D 213/85 C07D 239/42 C07C 279/18
Filing Date
2021-03-30
Application No.
17915675
Claims
19
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.